Sponsored
Sponsored
Media Summary: This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the This presentation provided an overview of CDRH's Medical Device Development Tools (MDDT) Program and explained what ... This presentation described sources of ANDA Program statistics and provided insight on key performance metrics. The session ...

Fda Nih 2024 D1s14 How - Detailed Analysis & Overview

This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the This presentation provided an overview of CDRH's Medical Device Development Tools (MDDT) Program and explained what ... This presentation described sources of ANDA Program statistics and provided insight on key performance metrics. The session ... This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ... This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ... This presentation introduced CBER's Manufacturers Assistance and Technical Training Branch (MATTB) and explained their ...

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ... This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ... This presentation provided information on the National Cancer Institute's Small Business Innovation Research (SBIR) ... This presentation discussed a rundown of the Do's and Don'ts from This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ... This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ...

The first of three Q&A discussion panels from the This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ... This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ... The purpose of this workshop is to discuss how the The last of three Q&A discussion panels from the This inaugural webinar was a collaborative effort between

The second of three Q&A discussion panels from the This presentation explored regulatory resources and avenues for obtaining early guidance from CBER's Office of Therapeutic ...

Photo Gallery

FDA-NIH 2024 | D1S14 - How Can DICE Help You?
FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program
GDF 2024 | D1S14 - ANDA Program Statistics
FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...
FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...
FDA-NIH 2024 | D1S08 - CBER’s Manufacturers Assistance and Technical Training Branch (MATTB)...
FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials
FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)
FDA-NIH 2024 | D1S01 - National Cancer Institute SBIR Development Center: Funding & Resources for...
FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title
FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource
AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation
View Detailed Profile
FDA-NIH 2024 | D1S14 - How Can DICE Help You?

FDA-NIH 2024 | D1S14 - How Can DICE Help You?

This presentation explained the role and function of the Division of Industry and Consumer Education (DICE) within the

FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program

FDA-NIH 2024 | D1S15 - CDRH Medical Device Development Tools (MDDT) Program

This presentation provided an overview of CDRH's Medical Device Development Tools (MDDT) Program and explained what ...

Sponsored
GDF 2024 | D1S14 - ANDA Program Statistics

GDF 2024 | D1S14 - ANDA Program Statistics

This presentation described sources of ANDA Program statistics and provided insight on key performance metrics. The session ...

FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...

FDA-NIH 2024 | D1S16 - Medical Device Coverage Initiatives: Connecting with Payors via the Payor...

This presentation explored medical device coverage initiatives and the role of the Payor Communication Task Force in connecting ...

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

This presentation provided comprehensive guidance on CDER's nonclinical resources for approaching First-in-Human (FIH) ...

Sponsored
FDA-NIH 2024 | D1S08 - CBER’s Manufacturers Assistance and Technical Training Branch (MATTB)...

FDA-NIH 2024 | D1S08 - CBER’s Manufacturers Assistance and Technical Training Branch (MATTB)...

This presentation introduced CBER's Manufacturers Assistance and Technical Training Branch (MATTB) and explained their ...

FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials

FDA-NIH 2024 | D1S06 - CDER’s Clinical Consideration for First-in-Human Trials

This presentation outlined CDER's clinical considerations for First-in-Human trials and presented general good practices for FIH ...

FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)

FDA-NIH 2024 | D1S02 - Overview of CDER’s Small Business & Industry Assistance (SBIA)

This presentation provided information about the Small Business and Industry Assistance (SBIA) and its mission. Topics ...

FDA-NIH 2024 | D1S01 - National Cancer Institute SBIR Development Center: Funding & Resources for...

FDA-NIH 2024 | D1S01 - National Cancer Institute SBIR Development Center: Funding & Resources for...

This presentation provided information on the National Cancer Institute's Small Business Innovation Research (SBIR) ...

FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title

FDA-NIH 2024 | D1S03 - A Reflection on Today’s Seminar’s Title

This presentation discussed a rundown of the Do's and Don'ts from

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation

AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation

This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ...

FDA-NIH 2024 | D1S07 - Q&A Discussion Panel 1

FDA-NIH 2024 | D1S07 - Q&A Discussion Panel 1

The first of three Q&A discussion panels from the

FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...

FDA-NIH 2024 | D1S12 - Early Development of Cellular and Gene Therapy in Oncology -Clinical...

This presentation highlighted key clinical regulatory issues encountered during early-phase development of cellular and gene ...

FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

FDA-NIH 2024 | D1S11 - Nonclinical Assessment of Cell and Gene Therapy (CGT) Products to Support....

This presentation provided guidance on nonclinical assessment of Cell and Gene Therapy (CGT) products to support IND ...

FDA & NIH Workshop on Reducing Animal Testing

FDA & NIH Workshop on Reducing Animal Testing

The purpose of this workshop is to discuss how the

FDA-NIH 2024 | D1S17 – Q&A Discussion Panel 3

FDA-NIH 2024 | D1S17 – Q&A Discussion Panel 3

The last of three Q&A discussion panels from the

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

This inaugural webinar was a collaborative effort between

FDA-NIH 2024 | D1S13 – Q&A Discussion Panel 2

FDA-NIH 2024 | D1S13 – Q&A Discussion Panel 2

The second of three Q&A discussion panels from the

FDA-NIH 2024 | D1S09 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP

FDA-NIH 2024 | D1S09 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP

This presentation explored regulatory resources and avenues for obtaining early guidance from CBER's Office of Therapeutic ...

Related Video Content

Real World Applications of Cloud Computing - GeeksforGeeks information

Jul 23, 2025 · So other application of cloud computing includes social applications, management application, business...

What is a Cloud Application? Definition, Pros & Cons + Examples information

Jul 29, 2025 · The term 'cloud application' is a fundamental component of modern computing. A cloud application, or...

Cloud computing - Wikipedia information

Cloud computing metaphor: the group of networked elements providing services does not need to be addressed or managed...

What is a cloud application? | Definition from TechTarget information

Mar 18, 2024 · What is a cloud application? A cloud application, or cloud app, is a software program where...

What is Cloud Computing? - Google Cloud information

The main cloud computing service models include infrastructure as a service offers compute and storage services,...

Sponsored